Payment overview · 2025
General Payments
$561.32
27 reported records · 10 companies
Healthcare provider profile · identity verified
David Wayne Heine, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRUNSWICK, GA · NPI 1750397899
Verified facts
What the public records show
CMS Open Payments records show David Wayne Heine, MD received $561.32 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.87 | 26.0% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.76 | 25.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.51 | 12.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $48.90 | 8.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.82 | 7.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.32 | 4.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.28 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.60 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.35 | 3.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.91 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.32 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $126.34 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.85 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.82 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $42.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $4.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 241 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
241 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 129 |
| Simvastatin | Simvastatin | 515 | 129 |
| Losartan Potassium | Losartan Potassium | 511 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 83 |
| Omeprazole | Omeprazole | 293 | 80 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 276 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 72 |
| Gabapentin | Gabapentin | 258 | 72 |
| Lisinopril | Lisinopril | 241 | 76 |
| Ozempic | Semaglutide | 241 | 51 |
| Allopurinol | Allopurinol | 237 | 55 |
| Meloxicam | Meloxicam | 232 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 56 |
| Metformin Hcl | Metformin Hcl | 196 | 56 |
| Metformin Hcl Er | Metformin Hcl | 190 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 188 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 51 |
| Glipizide Er | Glipizide | 184 | 52 |
| Potassium Chloride | Potassium Chloride | 178 | 51 |
| Furosemide | Furosemide | 163 | 51 |
| Atenolol | Atenolol | 151 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 140 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 37 |
| Trazodone Hcl | Trazodone Hcl | 136 | 31 |
| Azithromycin | Azithromycin | 122 | 98 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 33 |
| Eliquis | Apixaban | 109 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 28 |
| Alprazolam | Alprazolam | 98 | 23 |
| Tramadol Hcl | Tramadol Hcl | 97 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 28 |
| Prednisone | Prednisone | 86 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 27 |
| Lovastatin | Lovastatin | 75 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 18 |
| Spironolactone | Spironolactone | 75 | 23 |
| Bupropion Xl | Bupropion Hcl | 74 | 16 |
| Famotidine | Famotidine | 62 | 16 |
| Alendronate Sodium | Alendronate Sodium | 56 | 14 |
| Synthroid | Levothyroxine Sodium | 53 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 11 |
| Montelukast Sodium | Montelukast Sodium | 45 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 16 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 12 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Estradiol | Estradiol | 32 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 17 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Valsartan | Valsartan | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Carvedilol | Carvedilol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fluconazole | Fluconazole | 16 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Glipizide Xl | Glipizide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.32 · 27 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, FARXIGA, FREESTYLE LIBRE, General - Pain Management, JARDIANCE, LINZESS, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, WATCHMAN Access System, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error